Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...